Institutional Investors May Overlook Celcuity Inc.'s (NASDAQ:CELC) Recent US$51m Market Cap Drop as Long-term Gains Remain Positive

Key Insights Given the large stake in the stock by institutions, Celcuity's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 6 shareholders 14% of

Simply Wall StApr 13 21:14

Needham: Reiterates Celcuity (CELC.US) rating and adjusted from buy to buy rating, target price is $24.00.

Needham: Reiterates Celcuity (CELC.US) rating and adjusted from buy to buy rating, target price is $24.00.

Zhitong FinanceApr 12 18:20

Needham Reiterates Buy on Celcuity, Maintains $24 Price Target

Needham analyst Gil Blum reiterates Celcuity with a Buy and maintains $24 price target.

Analyst UpgradesApr 12 18:13

Celcuity: A Promising Buy in Healthcare Innovation and Personalized Oncology Solutions

TipRanksApr 12 18:07

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief

GlobeNewswireApr 4 19:05

Celcuity (NASDAQ:CELC): A Biotech With Game-Changing Blockbuster Potential

TipRanksApr 3 12:06